- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-814/24, Alexion Pharma Germany: Request for a preliminary ruling from the Landgericht München I (Germany) lodged on 27 November 2024 – Alexion Pharma Germany GmbH v Amgen Technology (Ireland) Unlimited Company and AMGEN GmbH
ECLI:EU:UNKNOWN:62024CN0814
62024CN0814
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2025/1081
(Case C-814/24, Alexion Pharma Germany)
(C/2025/1081)
Language of the case: German
Referring court
Parties to the main proceedings
Applicant: Alexion Pharma Germany GmbH
Defendants: Amgen Technology (Ireland) Unlimited Company, AMGEN GmbH
Questions referred
1.Does Article 8 of Regulation (EC) No 141/2000 (1) grant the holder of one or more indication-specific marketing authorisations for an orphan medicinal product a subjective legal position under civil law in the form of a right to market exclusivity, which the holder of market exclusivity may assert in civil proceedings against third parties if they interfere with the legal position?
2.If Question 1 is answered in the negative: Does Regulation (EC) No 141/2000, according to its overall objective, as reflected in particular in recital 8 of the regulation, grant the holder of one or more indication-specific marketing authorisations for an orphan medicinal product, over and above the prohibition on processing and authorisation by an authority laid down in Article 8 of that regulation, a subjective legal position under civil law in the form of a right to market exclusivity, which the holder of market exclusivity may assert in civil proceedings against third parties if they interfere with the legal position?
3.If Question 1 or 2 is answered in the affirmative: Do the claims of the holder of such a subjective civil-law right of market exclusivity in the event of interference with that legal position by third parties arise directly from EU law or are their scope and form governed by national law?
*
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ 2000 L 18, p. 1).
ELI: http://data.europa.eu/eli/C/2025/1081/oj
ISSN 1977-091X (electronic edition)
—
* * *